Received Jul 28, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Bells Palsy; This serious case was reported by a consumer via interactive digital media and described the occurrence of bell's palsy in a patient who received Herpes zoster (Shingrix) for prophylaxis. The patient received the 1st dose of Shingrix. The patient experienced bell's palsy (Verbatim: Bells Palsy) (serious criteria GSK medically significant and other: Serious as per reporter). The outcome of the bell's palsy was unknown. It was unknown if the reporter considered the bell's palsy to be related to Shingrix. The company considered the bell's palsy to be unrelated to Shingrix. Additional Information: GSK receipt date: 21-JUL-2026 This case was reported by a patient via interactive digital media. The patient developed Bell's palsy within a week of first Shingrix dose. The physician advised patient not to receive any further Shingrix vaccinations. It was asked to stop send messages. The batch number was not provided, and we are unable to contact the reporter.; Sender's Comments: A case of Bell's palsy, less than a week after vaccination with the 1st dose of Shingrix, in a patient. Based on the available information a possible causality that the event was caused by GSK vaccine product cannot be ascertained. Consent for further follow up has not been received.